mim8 novo nordisk - Search News

News

Novo Nordisk to sell Wegovy through telehealth firms

Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.

The Hill on MSN · 15h

Novo Nordisk partners with Ro, Hims and LifeMD to sell low-cost Wegovy

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular weight-loss drug Wegovy. The pharmaceutical company announced it would

MarketWatch · 21h

Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar -- Update

In a joint venture with Novo Nordisk, Hims & Hers will dispense all doses of Wegovy to Americans who buy eligible subscriptions, with plans starting at $599 a month. The offering

Zacks Investment Research on MSN20h

Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?

Novo Nordisk NVO is expected to beat estimates when it reports its first-quarter 2025 results before the opening bell on May ...

Nasdaq5d

Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?

Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon. Alhemo (concizumab) has been ...

Seeking Alpha1mon

Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors

as well as the launches of Mim8 and amycretin. What do I expect from Eli Lilly in the long term? I estimate Eli Lilly's non-GAAP EPS and revenue growth will be higher than Novo Nordisk's over ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

News

Novo Nordisk to sell Wegovy through telehealth firms

Trending now